目的:本文旨在分析病毒感染后引起的葡萄膜炎患者的临床特点及治疗方案。方法:收治1例经房水病原微生物宏基因组检测出病毒的葡萄膜炎患者,结合该患者情况及相关文献进行讨论与治疗。结果:患者经人免疫球蛋白及静脉激素冲击治疗后葡萄...目的:本文旨在分析病毒感染后引起的葡萄膜炎患者的临床特点及治疗方案。方法:收治1例经房水病原微生物宏基因组检测出病毒的葡萄膜炎患者,结合该患者情况及相关文献进行讨论与治疗。结果:患者经人免疫球蛋白及静脉激素冲击治疗后葡萄膜炎的症状迅速缓解,病情好转后出院。随访2个月,病情稳定,视力恢复良好。结论:葡萄膜炎是眼科常见的致盲性眼病,病毒感染是其重要原因。对于其引起的葡萄膜炎病人要做到早期明确诊断、个性化治疗以提升患者视力,改善疾病预后。Objective: This paper aims to analyze the clinical characteristics and treatment plans of patients with uveitis caused by viral infection. Methods: One patient with uveitis, in whom viruses were detected by metagenomic testing of the aqueous humor for pathogenic microorganisms, was admitted and treated. The patient’s condition was discussed in combination with relevant literature. Results: After treatment with human immunoglobulin and intravenous corticosteroid pulse therapy, the symptoms of uveitis in the patient rapidly relieved, and the patient was discharged after the condition improved. After 2 months of follow-up, the condition was stable, and the visual acuity recovered well. Conclusion: Uveitis is a common blinding eye disease in ophthalmology, and viral infection is an important cause of it. For patients with uveitis caused by viral infection, early and definite diagnosis and personalized treatment should be carried out to improve the visual function of patients and the prognosis of the disease.展开更多
Dear Editor,We report a rare case of lens coloboma and several notches with bilateral ectopia lentis in Marfan syndrome.This case was approved by the Ethics Committee of Aier Excellence Eye Hospital(2023KJB0004).Writt...Dear Editor,We report a rare case of lens coloboma and several notches with bilateral ectopia lentis in Marfan syndrome.This case was approved by the Ethics Committee of Aier Excellence Eye Hospital(2023KJB0004).Written informed consent was obtained from the patient.Lens coloboma and Marfan syndrome are of low incidence and seldom observed in the clinic.展开更多
Non-infectious uveitis(NIU),although a highly blinding but preventable cause of blindness around the world,has few approved pharmaceuticals for its treatment.Lack of access to effective treatment is likely a major cau...Non-infectious uveitis(NIU),although a highly blinding but preventable cause of blindness around the world,has few approved pharmaceuticals for its treatment.Lack of access to effective treatment is likely a major cause of poor visual outcomes in NIU.However,despite a revolution in rheumatologic disease treatment with the advent of multiple biologic therapeutics selectively targeting the immune response,there remains a gap in the long-term management of NIU.Adalimumab remains the only systemic medication approved for the treatment of NIU by the Food and Drug Administration(FDA).All other systemic treatments,including older anti-metabolites such as methotrexate and mycophenolate,are used offlabel for NIU,posing significant treatment challenges.Given the nature and rarity of the disease,there are few well designed,large,clinical trials evaluating the efficacy of novel therapeutic agents within this field.We therefore read with great interest Srivastava et al.’s randomized clinical trial on the efficacy of filgotinib,a Janus kinase inhibitor(JAKi),in active NIU(1).The early termination of the trial due to business considerations highlights the industry difficulty in FDA medication approval for NIU.展开更多
文摘目的:本文旨在分析病毒感染后引起的葡萄膜炎患者的临床特点及治疗方案。方法:收治1例经房水病原微生物宏基因组检测出病毒的葡萄膜炎患者,结合该患者情况及相关文献进行讨论与治疗。结果:患者经人免疫球蛋白及静脉激素冲击治疗后葡萄膜炎的症状迅速缓解,病情好转后出院。随访2个月,病情稳定,视力恢复良好。结论:葡萄膜炎是眼科常见的致盲性眼病,病毒感染是其重要原因。对于其引起的葡萄膜炎病人要做到早期明确诊断、个性化治疗以提升患者视力,改善疾病预后。Objective: This paper aims to analyze the clinical characteristics and treatment plans of patients with uveitis caused by viral infection. Methods: One patient with uveitis, in whom viruses were detected by metagenomic testing of the aqueous humor for pathogenic microorganisms, was admitted and treated. The patient’s condition was discussed in combination with relevant literature. Results: After treatment with human immunoglobulin and intravenous corticosteroid pulse therapy, the symptoms of uveitis in the patient rapidly relieved, and the patient was discharged after the condition improved. After 2 months of follow-up, the condition was stable, and the visual acuity recovered well. Conclusion: Uveitis is a common blinding eye disease in ophthalmology, and viral infection is an important cause of it. For patients with uveitis caused by viral infection, early and definite diagnosis and personalized treatment should be carried out to improve the visual function of patients and the prognosis of the disease.
基金Supported by Hunan Province Enterprise Joint Fund Project(No.2023JJ70040)Young and Middle-Aged Science and Technology Innovation Incubation Project of Aier Eye Group(No.AC2214D01)+1 种基金Free Exploration Program of the Scientific Research Foundation of Aier Eye Group in 2021(No.AF2102D6)Clinical Research Institute Research Fund Project of Aier Eye Group(No.AR2102D1).
文摘Dear Editor,We report a rare case of lens coloboma and several notches with bilateral ectopia lentis in Marfan syndrome.This case was approved by the Ethics Committee of Aier Excellence Eye Hospital(2023KJB0004).Written informed consent was obtained from the patient.Lens coloboma and Marfan syndrome are of low incidence and seldom observed in the clinic.
基金Unrestricted departmental grant from Research to Prevent Blindness.T.M.J.receives funding from the National Institutes of Health(K12TR005104).
文摘Non-infectious uveitis(NIU),although a highly blinding but preventable cause of blindness around the world,has few approved pharmaceuticals for its treatment.Lack of access to effective treatment is likely a major cause of poor visual outcomes in NIU.However,despite a revolution in rheumatologic disease treatment with the advent of multiple biologic therapeutics selectively targeting the immune response,there remains a gap in the long-term management of NIU.Adalimumab remains the only systemic medication approved for the treatment of NIU by the Food and Drug Administration(FDA).All other systemic treatments,including older anti-metabolites such as methotrexate and mycophenolate,are used offlabel for NIU,posing significant treatment challenges.Given the nature and rarity of the disease,there are few well designed,large,clinical trials evaluating the efficacy of novel therapeutic agents within this field.We therefore read with great interest Srivastava et al.’s randomized clinical trial on the efficacy of filgotinib,a Janus kinase inhibitor(JAKi),in active NIU(1).The early termination of the trial due to business considerations highlights the industry difficulty in FDA medication approval for NIU.
